ClinicalTrials.gg
Drug

Tocilizumab clinical trials

Also written Actemra, RoActemra, RO4877533 and R-1569.

studies test it
336
open now
52
in phase 3
122
first study started
2001

How each study uses tocilizumab is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study

Get an email when these change. Save the tocilizumab studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.

Get alerts for these studies
See an example email

Example · made-up studies

Breast cancer · Recruiting: 2 came in, 3 changed

What changed in your alerts, Oct 31 – Nov 6:

A study of drug A after surgery for early breast cancer

Came in · now Recruiting

Drug B with hormone therapy in advanced breast cancer

Changed

· Sites: 4 added, including Seoul and Busan

· Enrollment: 300 → 450 participants

Exercise during chemotherapy

Now Active, not recruiting

One email a week for all your alerts. Stop any time.

Approvals

The first approval found in each region, with its record

United States
8 Jan 2010 · ACTEMRA · BLA 125276 (FDA, Drugs@FDA)
European Union
16 Jan 2009 · RoActemra · EMEA/H/C/000955 (EMA)

From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out

How studies write it

Studies that test it under each name

Name

Tocilizumab
217
tocilizumab [RoActemra/Actemra]
41
RoActemra/Actemra
13
MRA(Tocilizumab)
11
RoActemra, Actemra
7

Brand

Actemra
86

Development codes

RO4877533
6
R-1569
5
BAT1806
2
MSB11456
2
BIIB800
1

Other names

RoActemra
51
MRA
5

Biosimilars

Tyenne
1

Studies by the year they started

334 studies that test it; most in 2020 (58); 2 more planned to start later

Studies that test tocilizumab, by start year
YearStudies
20011
20031
20046
20058
20062
20072
20086
200913
201019
201120
201222
201320
201418
201511
201612
201717
201815
20199
202058
202112
202210
202312
20249
202515
202616

By phase

A phase 1/2 study counts in both.

Early Phase 1
2
Phase 1
50
Phase 2
120
Phase 3
122
Phase 4
49
No phase
24

What it is tested for

Each study’s main condition, where its own words name it, so a study counts once.

Who runs them

Industry 130 · Other 206

Hoffmann-La Roche (98) · Assistance Publique - Hôpitaux de Paris (14) · Chugai Pharmaceutical (13) · National Institute of Allergy and Infectious Diseases (NIAID) (5) · Rigshospitalet, Denmark (4) · Massachusetts General Hospital (4) · Oslo University Hospital (4) · Peking Union Medical College Hospital (4)

Often tested with

Tested in the same studies.

Methotrexate (20) · Interleukin 1 Receptor Antagonist Protein (12) · Rituximab (8) · Abatacept (8) · Adalimumab (7) · Baricitinib (6) · Hydroxychloroquine (6) · Infliximab (6)

Coming up

From the study records. Dates are the sponsors’ own estimates and often move.

Tested against it · 4 phase 3 studies under way

Tocilizumab is the comparator. A study of two new drugs counts under both.

Reaching primary completion within a year · 16, 2 in phase 3

Studies that test tocilizumab, phase 3 first.

Studies

Open first, then newest update. How each study uses tocilizumab is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.

Testing it · 336

See all 336 studies that test tocilizumab →

Given beside what is tested · 90 — tocilizumab is usual care or a partner of the new treatment

Showing 20 of 90.

As the comparator · 19 — what is tested is compared with tocilizumab

What changed recently

From the registry's own updates since Oct 18, 2026.

Codes

What other systems call tocilizumab · ClinicalTrials.gg INT004804

  • MeSH (NLM) C502936tocilizumabOne source NLM
  • UNII (FDA) I031V2H011TOCILIZUMABConfirmed FDA, NLM, Wikidata
  • RxNorm 612865Confirmed FDA, Wikidata
  • Wikidata Q425154tocilizumabConfirmed FDA, NLM, Wikidata
  • NCI Thesaurus C84217TocilizumabOne source FDA
  • DrugBank DB06273One source Wikidata

“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.